by Clinical Neuropsychologist | Monday, November 11, 2024 | Neuroscience
Nature Neuroscience, Published online: 11 November 2024; doi:10.1038/s41593-024-01777-2Tyrosine kinase 2 (TYK2) critically regulates tau levels and aggregation by phosphorylating tau’s tyrosine 29. Partial inhibition of TYK2 mitigates tau pathologies in cells and...
by Clinical Neuropsychologist | Friday, November 8, 2024 | Dementia
Abstract INTRODUCTION Despite the recognized importance of including ethnic diversity in Alzheimer’s disease (AD) research, substantial knowledge gaps remain, particularly in Asian populations. METHODS RNA sequencing was performed on blood samples from the...
by Clinical Neuropsychologist | Friday, November 8, 2024 | Dementia
Abstract INTRODUCTION Semorinemab, an anti-tau monoclonal antibody, was assessed in two Phase II trials for Alzheimer’s disease (AD). Plasma and cerebrospinal fluid (CSF) biomarkers provided insights into the drug’s potential mechanism of action. METHODS...
by Clinical Neuropsychologist | Friday, November 8, 2024 | Neuroimaging
Abstract Background and Purpose Neuromyelitis optica spectrum disorder (NMOSD) affects the optic nerves and spinal cord but can also cause focal brain inflammation. Subcortical pathology may contribute to the etiology of cognitive deficits in NMOSD. Using myelin water...
by Clinical Neuropsychologist | Friday, November 8, 2024 | Dementia
Abstract Dementia prevention in Africa is critically underexplored, despite the continent’s high prevalence of modifiable risk factors. With a predominantly young and middle-aged population, Africa presents a prime opportunity to implement evidence-based...
